Atopic Dermatitis Is Systemic, and 'Doing Nothing' Has a Cost
Dermatology Times argues untreated atopic dermatitis isn't neutral: reframed as a systemic inflammatory disease, inaction carries its own risks beyond skin.
Topic
Topic
Dermatology Times argues untreated atopic dermatitis isn't neutral: reframed as a systemic inflammatory disease, inaction carries its own risks beyond skin.
A landmark pooled analysis of 11 trials finds itch relief in prurigo nodularis precedes visible lesion healing, reframing treatme…
Research links dupilumab to new-onset vitiligo and points to early recognition, a nemolizumab switch, and targeted topical therap…
Sanofi has signed a letter of intent with the pan-Canadian Pharmaceutical Alliance covering Dupixent across four dermatology and…
Dupilumab maintained durable efficacy and consistent safety across pediatric age groups in atopic dermatitis, Physicians Weekly r…
Sanofi and pCPA have signed a Letter of Intent covering Dupixent across four dermatology and respiratory indications. The bundled…
Sanofi and Canada's pCPA signed a Letter of Intent this week covering Dupixent (dupilumab) across four dermatology and respirator…
Sanofi and the pCPA have signed a letter of intent on Dupixent pricing across four dermatology and respiratory indications, openi…
A pregnancy registry reports reassuring findings on dupilumab exposure, giving dermatologists a concrete data point for counselin…
Tilrekimig has hit the EASI-75 primary endpoint in atopic dermatitis, with Eric Simpson, MD walking through the readout for HCPLi…